CLINICAL TRIALS PROFILE FOR BLU-5937
✉ Email this page to a colleague
Clinical Trials for BLU-5937
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03638180 ↗ | BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect | Completed | Bellus Health Inc | Phase 1 | This is a first-in-human study that will investigate the safety, tolerability and pharmacokinetics of ascending single and multiple doses of BLU-5937 using a double blind, placebo controlled, randomized, adaptive, single center study design. The influence of food on the pharmacokinetics of BLU-5037 will also be investigated. |
| NCT03979638 ↗ | A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough | Terminated | Bellus Health Inc | Phase 2 | This is a multi-center, randomized, double-blind, placebo-controlled, crossover, dose escalation study of BLU-5937 in subjects with unexplained or refractory chronic cough |
| NCT04678206 ↗ | Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough | Active, not recruiting | Bellus Health Inc | Phase 2 | This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 2b adaptive dose-finding study of BLU-5937 in participants with Refractory Chronic Cough (RCC). |
| NCT04693195 ↗ | A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis | Recruiting | Bellus Health Inc | Phase 2 | This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD). |
| NCT05244759 ↗ | Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937 | Completed | Bellus Health Inc | Phase 1 | This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of [14C]-BLU-5937. |
| NCT05570539 ↗ | Assessment of the Pharmacokinetics of BLU-5937 Extended Release Formulation | Recruiting | Bellus Health Inc | Phase 1 | This is a Phase 1, Single-Centre, Open-Label, Single-Part, Sequential Cross-Over Study Designed to assess the Pharmacokinetic Profile of BLU-5937 following Administration of Extended Release Formulation and an Immediate Release Reference Formulation in Healthy Male and Female Subjects |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for BLU-5937
Condition Name
Clinical Trial Locations for BLU-5937
Trials by Country
Clinical Trial Progress for BLU-5937
Clinical Trial Phase
Clinical Trial Sponsors for BLU-5937
Sponsor Name
